Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01384591 · ClinicalTrials.gov registry record · Phase 1

Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly

A Phase 1 study, sponsored by The University of Texas Medical Branch, Galveston.

Completed
Registry status
Phase 1
Development phase
6
Enrollment target

NCT01384591: Completed Phase 1 study, sponsored by The University of Texas Medical Branch, Galveston.

NCT01384591 is a Phase 1 study that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01384591, a Phase 1 study, has completed, sponsored by The University of Texas Medical Branch, Galveston.

COMPLETED
Registry status
Phase 1
Development phase
6 participants
Enrollment target

Study Summary

The general hypothesis is that elderly have diminished nutritive flow to skeletal muscle and impaired capacity for building muscle. In aging populations, this decreased ability to build muscle may represent a tipping point in the progression towards chronic physical frailty and disability. The goal is to examine whether novel pharmacologic therapies can improve nutritive blood flow to the muscles and muscle building in the elderly. The purpose of this study is 1) to determine if losartan administration will enhance blood flow and 2) to determine if N-acetylcysteine (NAC) will enhance blood flow. The investigators will study community dwelling, healthy older men and women (60-85 years). Subjects will be randomized to one of three groups: Experimental Group 1: Placebo losartan and placebo N-acetylcysteine (NAC). Experimental Group 2: losartan (25mg/dose) and placebo N-acetylcysteine (NAC). Experimental Group 3: N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo Subjects will admit to the clinic on day 1 of the study. Baseline testing consisting of leg blood flow (LBF), contrast enhanced ultrasound, handgrip testing and fatigue questionnaires. After testing is completed the subjects will recieve their first dose of NAC/ losartan/ placebo with dinner. Subjects will be fasted after 10 pm. On day 2, leg blood flow (LBF) will be measured approximately 12 hours post dose 1. Subjects will receive their second dose of NAC/ losartan/ placebo. Leg blood flow will be measured 1 hour and 2 hours post dose 2 of study interventions. The subjects will eat a meal and receive their third dose of the study intervention. Leg blood flow will be repeated at 1 hour and 2 hours post dose 3. Appoximately 30 minutes after dose 3 of the study intervention, handgrip testing will be performed and fatigue questionnaires completed.

Primary Outcome

Femoral Doppler Blood Flow was evaluated via Doppler ultrasound. For the two-dimensional (2-D) and Doppler ultrasound measurements, an ultrasound system (HDI-5000; Philips Medical Systems, Bothell, WA) with a linear array transducer (L7-4) was used with a transmit frequency of 12MHz. 2-D imaging of the common femoral artery will be performed in the long axis. Images will be triggered to the R wave of the cardiac cycle, and the femoral artery diameter will be measured using online video calipers.

Interventions

  • DRUG Losartan
  • DRUG N-acetylcysteine
  • DRUG Placebo losartan
  • DRUG Placebo N-acetylcysteine

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2011-07
Est. Completion 2015-05
Phase Phase 1

What the finished NCT01384591 record still lists

NCT01384591 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 4 interventions - of which Losartan is the first listed.

NCT01384591 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01384591 about?

NCT01384591 is a clinical study titled "Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly". The general hypothesis is that elderly have diminished nutritive flow to skeletal muscle and impaired capacity for building muscle. In aging populations, this decreased ability to build muscle may represent a tipping point in the progression towards chronic physical frailty and disability. The goal ...

What is the current status of trial NCT01384591?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-07. Estimated completion is 2015-05.

What interventions are being tested in trial NCT01384591?

The interventions under investigation include: Losartan (DRUG), N-acetylcysteine (DRUG), Placebo losartan (DRUG), Placebo N-acetylcysteine (DRUG).

Who is sponsoring clinical trial NCT01384591?

This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01384591's enrollment target sits among peer trials

6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01384591, the US trial registry maintained by the National Library of Medicine. NCT01384591 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.